Isabel Delany

Dr. Isabel Delany


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GAGiada Antonelli
Giada Antonelli
LCLuigia Cappelli
Luigia Cappelli
PCPaolo Cinelli
Paolo Cinelli
RCRossella Cuffaro
Rossella Cuffaro
BMBenedetta Manca
Benedetta Manca
FSFrancesca Schiavetti
Francesca Schiavetti
Traditional antimicrobial treatments consist of drugs which target different essential functions in pathogens. Nevertheless, bacteria continue to evolve new mechanisms to evade this drug-mediated killing with surprising speed on the deployment of each new drug and antibiotic worldwide, a phenomenon called antimicrobial resistance (AMR). Nowadays, AMR represents a critical health threat, for which new medical interventions are urgently needed. By 2050, it is estimated that the leading cause of death will be through untreatable AMR pathogens. Although antibiotics remain a first-line treatment, non-antibiotic therapies such as prophylactic vaccines and therapeutic monoclonal antibodies (mAbs) are increasingly interesting alternatives to limit the spread of such antibiotic resistant microorganisms. For the discovery of new vaccines and mAbs, the search for effective antigens that are able to raise protective immune responses is a challenging undertaking. In this context, outer membrane vesicles (OMV) represent a promising approach, as they recapitulate the complete antigen repertoire that occurs on the surface of Gram-negative bacteria. In this review, we present Escherichia coli and Pseudomonas aeruginosa as specific examples of key AMR threats caused by Gram-negative bacteria and we discuss the current status of mAbs and vaccine approaches under development as well as how knowledge on OMV could benefit antigen discovery strategies.

25 October 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
IVIrene Vacca
Irene Vacca
ETElena Del Tordello
Elena Del Tordello
GGGianmarco Gasperini
Gianmarco Gasperini
APAlfredo Pezzicoli
Alfredo Pezzicoli
MFMartina Di Fede
Martina Di Fede
IDIsabel Delany
Isabel Delany
Neisserial Heparin Binding Antigen (NHBA) is a surface-exposed lipoprotein ubiquitously expressed by Neisseria meningitidis strains and an antigen of the Bexsero® vaccine. NHBA binds heparin through a conserved Arg-rich region that is the target of two proteases, the meningococcal NalP and human lactoferrin (hLf). In this work, in vitro studies showed that recombinant NHBA protein was able to bind epithelial cells and mutations of the Arg-rich tract abrogated this binding. All N-terminal and C-terminal fragments generated by NalP or hLf cleavage, regardless of the presence or absence of the Arg-rich region, did not bind to cells, indicating that a correct positioning of the Arg-rich region within the full length protein is crucial. Moreover, binding was abolished when cells were treated with heparinase III, suggesting that this interaction is mediated by heparan sulfate proteoglycans (HSPGs). N. meningitidis nhba knockout strains showed a significant reduction in adhesion to epithelial cells with respect to isogenic wild-type strains and adhesion of the wild-type strain was inhibited by anti-NHBA antibodies in a dose-dependent manner. Overall, the results demonstrate that NHBA contributes to meningococcal adhesion to epithelial cells through binding to HSPGs and suggest a possible role of anti-Bexsero® antibodies in the prevention of colonization.

7 May 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LFLuca Fagnocchi
Luca Fagnocchi
SBSilvia Bottini
Silvia Bottini
GGGiacomo Golfieri
Giacomo Golfieri
LFLaura Fantappiè
Laura Fantappiè
FFFrancesca Ferlicca
Francesca Ferlicca
IDIsabel Delany
Isabel Delany
Most bacterial small RNAs (sRNAs) are post-transcriptional regulators involved in adaptive responses, controlling gene expression by modulating translation or stability of their target mRNAs often in concert with the RNA chaperone Hfq. Neisseria meningitides, the leading cause of bacterial meningitis, is able to adapt to different host niches during human infection. However, only a few sRNAs and their functions have been fully described to date. Recently, transcriptional expression profiling of N. meningitides in human blood ex vivo revealed 91 differentially expressed putative sRNAs. Here we expanded this analysis by performing a global transcriptome study after exposure of N. meningitides to physiologically relevant stress signals (e.g. heat shock, oxidative stress, iron and carbon source limitation). and we identified putative sRNAs that were differentially expressed in vitro. A set of 98 putative sRNAs was obtained by analyzing transcriptome data and 8 new sRNAs were validated, both by Northern blot and by primer extension techniques. Deletion of selected sRNAs caused attenuation of N. meningitides infection in the in vivo infant rat model, leading to the identification of the first sRNAs influencing meningococcal bacteremia. Further analysis indicated that one of the sRNAs affecting bacteremia responded to carbon source availability through repression by a GntR-like transcriptional regulator. Both the sRNA and the GntR-like regulator are implicated in the control of gene expression from a common network involved in energy metabolism.

10 May 2019 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
TBTarcisio Brignoli
Tarcisio Brignoli
AMAndrea G. O. Manetti
Andrea G. O. Manetti
RRRoberto Rosini
Roberto Rosini
AHAndreas F Haag
Andreas F Haag
Vincenzo ScarlatoVincenzo Scarlato
Vincenzo Scarlato
IDIsabel Delany
Isabel Delany
Staphylococcus aureus is a major human pathogen, and a leading cause of soft tissue and blood stream infections. One of the causes of its success as a pathogen is the peculiar array of immune evasion factors through which the bacterium avoids host defenses, where the staphylococcal protein A (SpA) plays a major role thanks to its IgG binding activities. Moreover, SpA has recently been proposed as a promising vaccine antigen. In this study, we evaluated the expression of SpA in a collection of staphylococcal strains, about 7% of which did not express SpA (SpA- strains), despite the presence of the gene. By a comparative genomic analysis, we identified that a mutation in the spa 5′ UTR sequence affecting the RBS is responsible for the loss of SpA in a subset of SpA- strains. Using a high-throughput qRT-PCR approach on a selected panel of virulence-related genes, we identified that the SpA- phenotype is associated with lower spa transcript levels and increased expression and production of capsule as well as other changes in the transcription of several key virulence factors. Our data suggest that the SpA- phenotype has occurred in geographically distinct strains through different molecular mechanisms including both mutation, leading likely to translation alterations, and transcriptional deregulation. Furthermore, we provide evidence that SpA- strains are highly susceptible to phagocytic uptake mediated by anti-capsule antibodies. These data suggest that S. aureus may alter its virulence factor expression pattern as an adaptation to the host or environment. Vaccination strategies targeting both SpA and capsule could therefore result in broader coverage against staphylococcal isolates than SpA alone.

5 July 2025 in npj Vaccines
Verified
Journal Article
Open access
PDF file
MSMarco Spinsanti
Marco Spinsanti
EMElisabetta Monaci
Elisabetta Monaci
GRGiacomo Romagnoli
Giacomo Romagnoli
GBGiada Buffi
Giada Buffi
AMAndrea Guido Oreste Manetti
Andrea Guido Oreste Manetti
EBErika Bartolini
Erika Bartolini
Gonorrhea, caused by Neisseria gonorrhoeae (GC) represents a significant public health threat that may be mitigated by an effective vaccine. Vaccines containing N. meningitidis outer membrane vesicles (OMVs), such as 4CMenB, demonstrated moderate effectiveness in preventing GC infections. Here, we developed NgG, an investigational GC vaccine based on Generalized Modules for Membrane Antigens (GMMA). NgG includes genetically detoxified OMVs from the FA1090 strain, engineered to reduce endotoxin activity and limit immune interference. NgG induced a robust immune response in mice and outperformed the comparator vaccine 4CMenB in several serological and functional tests. Immunization with GMMA from a FA1090 mutant, where major oligosaccharide epitopes are incomplete or absent, revealed that NgG lipooligosaccharide plays a major role in the breadth of functional responses, with protein component also contributing in some GC strains. These results suggest that NgG has the potential to block GC infection through various mechanisms, supporting further vaccine development.

16 April 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
GVGiacomo Vezzani
Giacomo Vezzani
VVViola Viviani
Viola Viviani
MAMartina Audagnotto
Martina Audagnotto
ARAlessandro Rossi
Alessandro Rossi
PCPaolo Cinelli
Paolo Cinelli
EFElisabetta Frigimelica
Elisabetta Frigimelica
Introduction: The 4CMenB vaccine licensed against serogroup B Neisseria meningitidis (MenB) contains three recombinant proteins and Outer Membrane Vesicles (OMV) from a New Zealand epidemic strain. The protective response mediated on differentmeningococcal strains has been historically ascribed to one of the four main vaccine antigens fHbp, NHBA, NadA, and PorA nominated as the immunodominant antigen of the OMV component. It is however accepted that the extensive cross-protection observed after vaccination may be attributed to other proteins in the OMV. Here we interrogate the B cell responses elicited in humans to the OMV component after 4CMenB vaccination to elucidate the contribution of additional OMV antigens to meningococcal cross-protection. Methods: Following the isolation of plasmablasts from vaccinees, the OMV-specific human monoclonal antibodies (HumAbs) were recombinantly expressed and characterized for their binding and functional activity on a panel of MenB strains. Their target specificity was assessed through a tailor-made protein array and Western blot.Results: We found that 18 HumAbs showing bactericidal activity were PorB-specific, 1 was LOS-specific and 4 functional HumAbs remain with unknown targets. We identified three functional classes within the PorB HumAbs, through binding and in silico docking experiments, likely to be elicited from distinct epitopes on PorB and highlighting this antigen as a multi-epitope immunogenic OMV component responsible for distinct cross-protection across multiple MenB strains. Interestingly three of the PorB HumAbs and the LOS-specific HumAb showed bactericidal activity also against gonococcus.Discussion: We identified PorB and LOS as antigens on the OMV that may be implicated in the real-world observations of moderate protection against gonorrhea infection after OMV-based vaccinations.